An observational study in Inflammatory Bowel Disease and Crohn Disease, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 13 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Crohn Disease by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Crohn Disease · Massachusetts General Hospital.
Among the 14 studies in Crohn Disease by Massachusetts General Hospital, this one is one of 3 that started in 2020, is one of 5 observational ones, and was the 6th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →7 of the 14 studies in Crohn Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–99
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 13 Years to 20 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 31 across the 9 interventional studies, 50 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
4 of the studies in Crohn Disease by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT04565821Massachusetts General HospitalFeasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | 2027-04-30 |
| NCT07033208Massachusetts General HospitalFeasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance | 2027-04-30 |
| NCT05332639Massachusetts General HospitalPersonalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Crohn Disease by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will be evaluating bone marrow composition via magnetic resonance imaging in newly diagnosed adolescents with Crohn disease (CD) compared to healthy, matched controls. The investigators will also be assessing their bone mineral density via other imaging modalities, including dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. This longitudinal project will focus on abnormalities in bone marrow composition, and specifically whether adolescents with newly diagnosed CD exhibit increased bone marrow fat, its association with bone mineral density (BMD) and the underlying pathophysiology, including bone turnover markers and immune cellular/molecular parameters.
Less than optimal bone health has been seen in children that have inflammatory bowel disease (IBD), including Crohn disease (CD). This can present as low bone density or altered bone structure, weakening the bones and increasing fragility and fracture risk. As adolescence is especially important in bone development, conditions such as CD during this time can lead to long term bone issues. The underlying mechanisms are not well understood, but what is known is that red bone marrow converts to fat-rich yellow marrow. This study aims to focus on abnormalities in bone marrow, and specifically whether adolescents who have been diagnosed with CD have more bone marrow fat.
The primary hypothesis is that newly diagnosed CD is associated with increased fat levels in bone, which is associated with decreased bone formation and suboptimal bone health. The central objective is to obtain longitudinal data on the differences in bone marrow between healthy adolescents and those with CD. Long term, the investigators want to study how abnormal fat tissue and suboptimal bone health relate to each other.
The study involves 46 adolescents recently diagnosed with CD and 46 healthy adolescents. Eligibility criteria include no other chronic diseases that affect bone health and limited use of bone altering medications in the last three months. The CD adolescents will be matched with healthy adolescents based on age, stage of puberty, and BMI percentile. Additional data on CD participants will be collected via a chart review that will enable us to more fully characterize their CD.
Imaging will include MRIs of the knee. Measurements will include a visual assessment and quantitative marrow fat analysis, dual-energy X-ray absorptiometry (DXA), and peripheral quantitative computed tomography (pQCT). All scans will be for research purposes only. The MRIs will be evaluated for any abnormalities, and if there is an incidental finding, it will be reported to the primary care physician.
Additionally, blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
This study's planned enrollment of 92 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The experimental group will be adolescents aged 13-20 with newly diagnosed CD (within 3 months of diagnosis, based on histologic diagnosis and verified with their gastroenterologist).
The control group will be matched for age (within 1 year), pubertal stage (based on Tanner staging), and BMI percentile. Tanner staging will be based on clinically documented Tanner stage by GI physician for participants with CD and by their primary care physician for control participants. If there is no documented Tanner staging, then it will either be performed by the participants primary care physician, or by a pediatric endocrinologist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group will be 46 adolescents, ages 13-20, who have been recently (within 3 months) diagnosed with Crohn Disease. All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed.
Diagnostic Test: Coronal T1 weighted spin echo images · Diagnostic Test: Spin-lattice relaxation (T1) · Diagnostic Test: Magnetic resonance spectroscopy · Diagnostic Test: Blood Draw
Controls will be matched for age, Tanner staging, and BMI percentile. All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed.
Diagnostic Test: Coronal T1 weighted spin echo images · Diagnostic Test: Spin-lattice relaxation (T1) · Diagnostic Test: Magnetic resonance spectroscopy · Diagnostic Test: Blood Draw
Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
Bone marrow adiposity by magnetic resonance imaging (MRI)
Change in Bone marrow adiposity measured by MRI (T1 maps)
Time frame: Baseline and One Year follow-up
Magnetic resonance spectroscopy (MRS)
Change in T2 corrected fat/(fat+ water) ratios
Time frame: Baseline and One Year follow-up
Total body bone mineral density Z-score by Dual-energy X-ray absorptiometry (DXA)
Change in Total body BMD Z-score
Time frame: Baseline and One Year follow-up
Spine BMD Z-score by DXA
Change in Lumbar spine BMD Z-score
Time frame: Baseline and One Year follow-up
Spine apparent density Z-score by DXA
Change in Lumbar spine bone mineral apparent density (g/cm3)
Time frame: Baseline and One Year follow-up
Volumetric bone mineral density (vBMD)
Change in Quantitative computed tomography (pQCT) scans will be obtained at sites 3%, 38%, and 66% of tibial length proximal to the distal growth plate
Time frame: Baseline and One Year follow-up
Bone strength by quantitative computed tomography pQCT
Change in PQCT scans will be obtained at sites 3%, 38%, and 66% of tibial length proximal to the distal growth plate
Time frame: Baseline and One Year follow-up
Bone Formation Marker #1
Change in bone formation assessed by osteocalcin (ng/mL)
Time frame: Baseline and One Year follow-up
Bone Formation Marker #2
Change in bone formation assessed by procollagen type 1 N-terminal propeptide (ng/mL)
Time frame: Baseline and One Year follow-up
Bone Resorption Marker
Change in bone resorption assessed by c-telopeptide (pg/ml)
Time frame: Baseline and One Year follow-up
Immune Studies
Bulk RNA-sequencing on peripheral blood to evaluate molecular gene signatures that correlate with various bone imaging phenotypes; these will then be used to inform development and validation of a Mass Cytometry by Time-of-Flight panel that will be used on matched peripheral blood mononuclear cells samples.
Time frame: Baseline and One Year follow-up
Current Crohn's Disease Activity
Current Crohn's disease activity will be assessed using the pediatric Crohn disease activity index (PCDAI). The assessment will be made based on questionnaires answered.
Time frame: Baseline and One Year follow-up
Physical Activity
Physical activity will be assessed through a physical activity questionnaire
Time frame: Baseline and One Year follow-up
Dietary Calcium Intake
Dietary calcium intake will be assessed through a targeted dietary questionnaire
Time frame: Baseline and One Year follow-up
Plan to share: No
Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 75 months is above that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →